KYS Vision Reports Clinical Trial Results of Its Remote Physiologic Monitoring System for Patients With Chronic Retinal Conditions
NEW YORK, Oct. 31, 2022 (GLOBE NEWSWIRE) -- KYS Vision, Inc., an eye care digital health company, today announced clinical trial results of its Macustat macular function scan for the remote monitoring of central retinal function.
- NEW YORK, Oct. 31, 2022 (GLOBE NEWSWIRE) -- KYS Vision, Inc., an eye care digital health company, today announced clinical trial results of its Macustat macular function scan for the remote monitoring of central retinal function.
- The study is one of the first clinical trials to validate the clinical utility of real-world remote physiologic monitoring using an on-demand vision-as-a-service (VaaS) extension to the specialty retina clinic to enable remote monitoring of patients with chronic diseases such as AMD, diabetic retinopathy, and other retinal conditions.
- Macustat is a part of a suite of cloud-based VaaS digital health applications which includes remote monitoring tests for glaucoma, AMD, DME, and other chronic conditions.
- KYS Vision is a digital eye health company for remote patient monitoring and care management using a next-generation vision-as-a-service technology service model.